MDS Virtual Congress 2020

SEPTEMBER 12–SEPTEMBER 16 www.mdscongress.org

MDS-0820-029

Basic Science Abstracts

MDS Virtual Congress 2020 Basic Science Abstracts _________________________________________________________

22 Modeling Cerebellar Limb Dysmetria and Impaired Spatial Memory in Rats Using Lamivudine: A preliminary study E. Akang, O. Dosumu, S. Afolayan, R. Agumah, A. Oremosu, A. Akanmu (Anatomy, College of Medicine, University of Lagos.)

23 Novel Dentato-Olivo-Luysian Atrophy in a Greek Family S. Alshimemeri, K. Yoshida, N. Visanji, E. Rogaeva, R. Munhoz, E. Slow, A. Lang, G. Kovacs (The Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network)

46 Genetic, biochemical and clinical findingss in Friedreich’s ataxia patients – relationship with the disease severity R. Moganty, D. Pathak, A. srivastava, s. Gulati (All India Institute Of Medical Sciences)

58 Clinical and genetic abnormalities in patients with Friedreich's ataxia: A genotype-phenotype correlation I. Singh, I. Ahmed, S. Shaykya, A. Srivastava (All India Institute of Medical Sciences)

60 Clinical correlation with the Genotype of Friedreich’s Ataxia (FRDA) patients in Indian population A.K. Srivastava, I. Ahmad, P. Sharma, M. Seth, U. Shamim, I. Singh, R. Rajan, MV.P. Srivastava, F. Mohammad (All India Institute of Medical Sciences)

68 Nivolumab-induced choreoathetosis in a woman with lung cancer – A case report with review of the literature J. Johansson Lindgren, M. Esbjörnsson, E. Tüzün, H. Griph, D. Van Westen, G. Sahin (Hässleholm Hospital)

74 Case Report: Pseudoatetosis as Manifestation of the Vitamin B12 Deficit J. Vargas (MÉDERI/HIJS)

87

Compared the effects of probiotics and Anti-PD

particles on the behavior of Parkinson's

disease mice model

X.H. Zhao, Y.B. Wang, J. Yang, L.Y. Zhang, H.Q.

Liu, H.J. Sui (The People’s Hospital of Pudong)

105 Abrogation of neuroinflammation and behavioural deficit by Chlorogenic acid and Tinosporia cordiofolia in MPTP-Induced Parkinsonian mice model via suppressing NF-κB pathway D. Singh, M. Singh (SHUATS)

127 Mutation screening and clinical features analysis in patients with early-onset primary dystonia X.J. Gu, J. Yang, L.Y. Zhang, Q.Q. Wei, H.F. Shang (West China Hospital, Sichuan University)

128 Concordance of different evaluation approaches of non-motor symptoms in patients with cervical dystonia V. Han, K. Kulcsarova, J. Ventosa, Z. Gdovinova, M. Skorvanek (Safarik University)

130 Frequency and phenotypic spectrum of ANO3 dystonia: A single-center cohort study L.T. Jiang, L.X. Li, Y. Liu, X.L. Zhang, Y.G. Pan, L.J. Jin (Shanghai Tongji Hospital, Tongji University School of Medicine)

142 The Dystonia Coalition Natural History Project: An Available Research Resource S. Norris, H. Jinnah, L. Wright, G. Kilic-Berkmen, J. Hieshetter, D. Peterson, S. Pirio-Richardson, J. Perlmutter (Washington University School of Medicine)

146 Development of novel treatment strategies for SGCE dystonia using patient-derived induced pluripotent stem cells (iPSCs) S. Staege, A. Kutschenko, P. Seibler, K. Grütz, A. Hermann, F. Wegner (Hannover Medical School)

155 Neural bases of dystonia penetrance and manifestation S. Khosravani, G. Chen, K. Simonyan (Mass. Eye and Ear Infirmary)

161 Regional, Not Global, Functional Connectivity Contributes to Isolated Focal Dystonia S. Norris, A. Morris, M. Campbell, M. Karimi, A. Babatunde, R. Paniello, A. Snyder, J. Mink, J. Perlmutter (Washington University School of Medicine)

165 Difference in pallidal single unit activity in cervical dystonia with jerky and sinusoidal head tremor A. Sedov, S. Usova, U. Semenova, A. Gamaleya, A. Tomskiy, H. Jinnah, A. Shaikh (Semenov Institute of Chemical Physics, Russian Academy of Sciences)

168 Distinct maladaptive and compensatory wiring patterns in penetrant and non-penetrant dystonia mutation carriers A. Vo, K. Schindlbeck, N. Nguyen, A. Rommal, M. Niethammer, D. Eidelberg (The Feinstein Institute for Medical Research)

184 Age at onset and Parkinson’s disease progression G. D'Urso, K. Taylor, T. Kustermann, N. Pavese, G. Pagano (Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area)

188 Incidence and survival of psychosis in patients with Parkinson’s Disease (1991-2010) M. Hajeb, C. Stang, E. Camerucci, T. Turcano, A. Mullan, P. Martin, V. Abler, M. Splett, N. Rashid, J. Bower, M. Mielke, R. Savica (Myo Clinic)

210 Quantitative method for designing appropriate longitudinal follow-up frequency with application to Parkinson’s disease cognition research

L. Suttner, S. Xie (Department of Biostatistics, Epidemiology and Informatics; University of Pennsylvania)

228 The role of polymorphic allelic variants of the VEGFα and TGFβ gene in the development of cerebrovascular disorders in patients with metabolic syndrome S.h. Shokhimardonov, S.h. Xudjanov, F. Shermuhammedova, S.h. Kuzieva (Tashkent Medical Academy)

231 First Scientific Description of the Hepato-Lenticular Degeneration D. Labunskiy, S. Kiryukhina, N. Kolmykova (Ogarev Mordovia State University)

249 Cardiovascular risk factors in a pre-manifest and manifest population of Huntington's disease E. Gatto, N. Gonzalez Rojas, M. Cesarini, J. Etcheverry, G. Da Prat (Instituto Neurociencias Buenos Aires (INEBA))

253 Cytokines and Brain Specific Antibodies in Experimental Cellular and Molecular Treatment of Huntington's Diseases D. Labunskiy, S. Kiryukhina, V. Podsevatkin (Ogarev Mordovia State University)

266 The roles of Huntingtin Associated Protein 40 in Huntingtin functions and Huntington’s disease pathogenesis S. Xu, G. Li, X. Ye, L. Ye, Z. Xu, E. Furr Stimming, S. Zhang (The Brown Foundation Institute of Molecular Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston)

293 4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates T. Di Paolo, M. Bourque, R. Snodgrass (CHU de Quebec-Université Laval)

294

Copper induced neurobehavioral features of

Parkinson’s disease and oxidative stress and

their abatement by Eugenol

A. Kumar, B. Sharma (University of Allahabad)

295 hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk J. Li, H.L. Wang, M.W. Wang (Department of Neurology, the First Hospital of Hebei Medical University)

296 Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson's disease P. Panda, S. Ahmed, V. Naidu (NIPER-Guwahati)

297 Neuroprotective effects of allicin microemulsion against intrastriatal rotenone and manganese induced Parkinsonism in rats S. Singh (ISF College of Pharmacy)

298 Preclinical pharmacology and early clinical development of dopamine D1 positive allosteric modulators (D1PAMs) with therapeutic potential for neuropsychiatric disorders K. Svensson, H. Meltzer, K. Biglan (Eli Lilly and Company)

299 Oral treatment of the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS) with the neuro-inflammation inhibiting compound PRI-003 D. Willbold, J. Post-Schulz, A. Schaffrath, A. Willuweit, J. Kutzsche (Forschungszentrum Jülich)

305

Hyperpolarization of the subthalamic nucleus

alleviates hyperkinetic movement disorders

C.-H. Tai, S.-H. Tseng, T.-R. Wang, M.-T. Hsu, C.-

C. Kuo (National Taiwan University Hospital)

311 MR Conditional Labeling for DBS – Basic Physics for the Non-Specialist M. Conroy, S. Falowski, D. Sayed, L. Poree, K. Chakravarthy, R. Banerjee, J. Kramer (Medtronic)

313 Paroxysmal Kinesigenic Dyskinesia: Case series from Çukurova University, Turkey M. Demirkiran, M. Balal, A. Bisgin, S. Bozdogan (Cukurova University School of Medicine)

320 Hospitalization causes and condition at discharge of Parkinson's disease patients in Mexican public institutions between 2011 and 2017 R. Janssen-Aguilar, V. Villasuso-Alcocer, C. Rivas-Berny, N. Méndez-Domínguez, R. Leal-Ortega (Universidad Marista de Mérida)

324 Visuomotor reaction time can predict IQ in children S. Kiselev (Ural Federal University)

326 A novel phasic and restricted basal ganglia thalamocortical subcircuitry model

D. Kumbhare, G. Weistroffer, M. Baron (Virginia Commonwealth University)

335 Endovascular therapy in acute ischemic stroke(AIS) M. Munteanu (Regina Maria Private Medical Care)

346 Effect of herbal medicine against Parkinson’s Diseases- An in silico studies S. Subramani, Y. Gupta, R. Sharma, P. Prasad (Jiwaji University)

35 Identification and characterization of anti-prionic compounds that disassemble Tau prions as a novel therapeutic approach for tauopathies D. Willbold, T. Altendorf, W. Hoyer, J. Mohrlüder (Forschungszentrum Jülich)

371 Unraveling the role of amylin oligomers in synucleinopathies I. Martinez Valbuena, R. Valenti Azcarate, C. Caballero, I. Marcilla Garcia, I. Amat-Villegas, J. Sanchez, G. Marti-Andres, L. Armengou, M.R. Luquin Piudo (Center for Applied Medical Research and Clinica Universidad de Navarra - University of Navarra)

374 Development and Characterization of an Ultrasensitive Assay Platform for Detection of PD Associated alpha-Synuclein Oligomers in Human Blood D. Robakis, A. Chiu, B. Chang, R. Rubenstein (SUNY Downstate Health Sciences University)

376 Discrimination of alpha-synuclein strains and sub-strains in Synucleinopathies M. Shahnawaz, A. Mukherjee, S. Pritzkow, N. Dinamarca, F. Wang, P. Rabadia, C. Soto (Mitchell Center for Alzheimer’s disease and Related Brain Disorders, University of Texas Medical School at Houston)

394 The role of attention networks in walking in Parkinson’s disease R. Drake, G. Eskes (Dalhousie University)

399 Regional cortical thickness alterations in PD patients with cognitive impairment

V. Goyal, S. Chaudhary, A. Ankeeta, S. Kumaran, P. Bhat (Medanta, The Medicity)

422 How Parkinson’s Disease Affects Working Memory L. Montaser Kouhsari, A. Bakkour, D. Shohamy (Columbia University)

427 Decreased Regional Cholinergic Signaling in Parkinson's Disease J. O'Donnell, Y. Zhou, M. Campbell, S. Mansor, B. Maiti, Z. Tu, J. Perlmutter (Washington University School of Medicine)

432 Comparison of gait pattern characteristics during Parkinson's disease progression - Analysis of gait during the dual-task walking S. Radovanovic, V. Markovic, I. Stankovic, S. Gluscevic, I. Petrovic, V. Kostic (Institute for Medical Research, University of Belgrade)

444 Clock Drawing Test does not Differentiate Alzheimer’s Disease from Parkinson’s Disease Dementia S. Tezcan Aydemir, M. Kuzu Kumcu, C. Akbostancı (Sincan Dr. Nafiz Körez Government Hospital)

450 Candidate plasma miRNAs and EV protein as novel biomarkers in Parkinson's disease patients with cognitive impairment and dementia R.-M. Wu, Y.Z. Tsai, M.-C. Kuo, Y.u. Yoshioka, Ko.j. Ueda, Ta.k. Ochiya, S.-P. Lin (Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University)

451 Neuroprotective propensity of marmelosin against 6-OHDA-induced cognitive impairment and apoptosis via upregulation of PI3K/Akt pathway E. Yadav (Sam Higginbottom University of Agriculture Technology & Sciences)

452 Identification and clinical characteristics of Mild Cognitive Impairment in Parkinson’s disease J. Yang, E. Forbes, D. Pourzinal, K. McMahon, D. Copland, G. Byrne, J. O'Sullivan, L. Mitchell, N. Dissanayaka (University of Centre for Clinical Research)

453 Cerebral microvascular injury provoked by alpha-synuclein preformed fibrils exacerbates cognitive dysfunction in Parkinson's disease Q.X. Zhang, Y.Y. Gao, L.J. Wang (Guangdong Provincial People’s Hospital)

456 Cognitive profiling of patients with neurodegenerative disorders I. Zhukova, E. Kolupaeva, N. Zhukova, O. Izhboldina, M. Nikitina, A. Latipova, S. Shtaymets, I. Mironova, Z.h. Kislukhina, L. Tkachenko, A. Agasheva, D. Novotnyy (Siberian State Medical University)

457 Parkinson’s disease polygenic risk score and brain structure in neurologically healthy individuals N. Abbasi, L. Krohn, U. Vainik, Z. Gan-Or, A. Dagher (McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University)

458 The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson's disease: a pilot study G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, A. Baitimerov, G. Tayupova, R. Magzhanov (Institute of Biochemistry and Genetics Ufa Research Study Center)

459 Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients and controls: the PPMI study R. Alcalay, P. Wolf, MS.R. Chiang, K. Helesicova, X.K. Zhang, K. Merchant, S. Hutten, C. Scherzer, C. Caspell-Garcia, C. Blauwendraat, K. Nudelman, T. Foroud, Z. Gan-Or, T. Simuni, L. Chahine, O. Levy, D. Zheng, G. Li, P. Sardi (Columbia University)

463 An introduction to the Global Parkinson's Genetics Program (GP2) C. Blauwendraat, E. Riley, A. Singleton (National Institutes on Aging)

469 Northwestern University Feinberg School of Medicine Parkinson’s disease and Movement Disorders Center Biorepository: bringing the clinic and lab together A. Hernandez, S. Lubbe, T. Simuni, D. Bega, D. Krainc, N. Mencacci, R. Modiest, P. Opal, C. Taylor, N. Shetty, R. Malkani, J. Blackburn (Northwestern University)

471 Moderately frequent and private variants in PRKN are associated with late-onset Parkinson’s disease F. Hopfner, S.M. Müller, S.S. Szymczak, O. Junge, L. Tittmann, S. May, K. Lohmann, G. Grallert, B. Schormair, J. Winkelmann, B. Mollenhauer, C. Trenkwalder, W. Maetzler, D. Berg, M. Kasten, C. Klein, G. Hoeglinger, T. Gasser, G. Deuschl, A. Franke, M. Krawczak, A. Dempfle, G. Kuhlenbäumer (Hannover Medical School)

473 Beta-Glucocerebrosidase Activity in GBA-linked Parkinson's Disease: The Type of Mutation Matters Y.E. Huh, M.S. Chiang, J. Locascio, Z. Liao, G. Liu, K. Choudhury, Y. Kuras, I. Tuncali, A. Videnovic, A. Hunt, M. Schwarzschild, A. Hung, T. Herrington, M. Hayes, B. Hyman, A.-M. Wills, S. Gomperts, J. Growdon, S. Sardi, C. Scherzer (APDA Center for Advanced Parkinson Research, Harvard Medical School, Brigham & Women's Hospital)

…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………….474 Virtual Assessment of LRRK2 Carriers to Optimize Research in Parkinson Disease (VALOR-PD): A Comparison to Traditional Cohorts S. Jensen-Roberts, T. Myers, K. Amodeo, S. Sharma, R. Alcalay, E. Dorsey, R. Holloway, R. Schneider (University of Rochester)

475 A Fluctuating Qualitative Dermatoglyphic Trait, Dankmeijer’s and Furuhata’s Index as a Risk Marker in Diabetic Parkinson’s Patients of Guyana: A Case-Control Study A. Jha, S. D'costa, W. White, M. Chapp, D. Kanhai (University of Nicaragua)

483 Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease J. Lee, P. Pinares-Garcia, H. Loke, S. Ham, E. Vilain, V. Harley (Hudson Institute of Medical Research)

489 Parkinson’s disease polygenic risk prediction and haplotype analysis in a South American cohort D. Loesch, A. Horimoto, E. Sarihan, M. Cornejo-Olivas, L. Torres, M. Inca-Martinez, P. Mazzetti, C. Cosentino, E. Dieguez, V. Raggio, A. Lescano, V. Tumas, V. Borges, H. Ferraz, C. Rieder, A. Schumacher-Schuh, B. Lopes Santos-Lobato, C. Velez-Pardo, M. Jimenez-Del-Rio, F. Lopera, P. Chana-Cuevas, W. Fernandez, G. Arboleda, H. Arboleda, C. Arboleda-Bustos, D. Yearout, C. Zabetian, T. Thornton, T. O'Connor, I. Mata (University of Maryland School of Medicine)

499 Interest of multiplex ligation-dependent probe amplification assay to identify pathogenic mutations in Parkinson’s disease patients E. Mutez, M. Swiderski, L. Defebvre, M.C. Chartier-Harlin, V. Huin (Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition)

502 Sensitive biomarker of Parkinson’s disease linked to mutations in the glucocerebrosidase gene S. Pchelina, M. Nikolaev, A. Kopytova, G. Baydakova, K. Senkevich, I. Miliukhina, T. Usenko, A. Emelyanov, E. Zakharova (Petersburg Nuclear Physics Institute, NRC “Kurchatov Institute”)

505 LRRK2 p.G2019S and p.N2081D variants as modifiers of glucocerebrosidase activity K. Senkevich, E. Yu, L. Krohn, U. Rudakou, J. Ruskey, F. Asayesh, K. Mufti, S. Laurent, D. Spiegelman, S. Fahn, C. Waters, P. Sardi, G. Rouleau, R. Alcalay, Z. Gan-Or (Montreal Neurological Institute, McGill University)

508 Burden of variants in Parkinson’s disease-associated genes in GBA mutation carriers Y.L. Sosero, E. Yu, P. Saini, L. Krohn, U. Rudakou, J. Ruskey, F. Asayesh, M. Estiar, S. Fahn, C. Waters, O. Monchi, Y. Dauvilliers, A. Espay, N. Dupré, L. Greenbaum, G. Rouleau, S. Hassin-Baer, E. Fon, R. Alcalay, Z. Gan-Or (McGill University)

509

DJ1 and α-Synuclein as CSF biomarkers and

gene polymorphisms: association with clinical

parameters in Parkinson’s disease

T. Syed, T. SD, R. Kandadai, V. Kutala, R.

Borgohain (Nizam's Institute of Medical sciences)

511 Is early-onset of levodopa-induced dyskinesia a predictor of GBA mutation? A next-generation sequencing study of young-onset Parkinson’s disease patients in Thailand S. Thanprasertsuk, P. Phowthongkum, T. Hopetrungraung, C. Poorirerngpoom, T. Satirapatya, P. Wichit, O. Phokaewvarangkul, K. Vongpaisarnsin, S. Bongsebandhu-phubhakdi, R. Bhidayasiri (Faculty of Medicine, Chulalongkorn University)

512 mRNA level and variants of the SCARB2 gene in the pathogenesis of Parkinson’s disease T. Usenko, A. Bezrukova, D. Bogdanova, A. Kopytova, A. Emelyanov, I. Miliukhina, A. Timofeeva, S. Pchelina (Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute»)

513 LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression T. Usnich, N. Schell, E.-J. Vollstedt, V. Skrahina, X. Bogdanovic, N. Koleva-Alazeh, I. Csoti, T. Förster, A. Heuer, N. Brüggemann, P. Bauer, M. Kasten, A. Rolfs, C. Klein (Institute of Neurogenetics)

515 TET2-mediated Cdkn2A DNA hydroxymethylation in dopaminergic neuronal injury of Parkinson's disease Y.C. Wu, T.T. Wu, X. Li, T. Liu (Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine)

516 Effect of P2X4 Signal Axis on Iron Metabolism in Parkinson’s Disease Animal Model A. Xie, J. Gao, J. Ma (Affiliated Hospital of Medical College Qingdao University)

517 H1/H2 MAPT Haplotype and Parkinson's Disease in an Ashkenazi Jewish Cohort

G. Yahalom, L. Greenbaum, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, S. Hassin-Baer, Z. Gan-Or, J. Ruskey, E. Leveille, U. Rudakou, L. Krohn, G. Rouleau (Saare Zedek Medical Center)

521 GCH1 variants contribute to risk and earlier age at onset in Parkinson's disease Y. Zhao, H. Pan, Q. Sun, Q. Xu, X. Yan, J. Li, B. Tang, J. Guo (Xiangya Hospital, Central South University)

523 Type-3 Metabotropic Glutamate Receptors and Parkinson’s Disease: Preclinical Studies and Human Genetics M. Alborghetti, L. Di Menna, A. Traficante, V. Bruno, J. Monn, F. Nicoletti, F.E. Pontieri, E. Bianchini, G. Spalletta, M. Borro, M. Simmaco, G. Battaglia (Neuroscience, Mental Health and Sensory Organs (NESMOS))

526 Male-specific exacerbation of susceptibility to α-synuclein pre-formed fibrils by developmental dieldrin exposure in mice A. Bernstein, A. Gezer, J. Kochmanski, S. VanOeveren, A. Cole-Strauss, C. Kemp, J. Patterson, K. Miller, N. Kuhn, D. Herman, A. McIntire, J. Lipton, K. Luk, S. Fleming, C. Sortwell (College of Human Medicine, Michigan State University)

527 Characterization of Lewy bodies-induced neurodegeneration and synucleopathy in wild-type mice E. Bezard, L. Zhang, X. Yu, X. Sun, Y. Zhang, G. Ran, S. Dovero, M. Persillet, P. Fernagut, B. Dehay, C. Qin (Institute of Neurodegenerative Diseases)

528 Glucocerebrosidase Deficiency Mediates Propagation of Protein Aggregation via Extracellular Vesicle Dysregulation K. Jewett, R. Thomas, C. Phan, G. Milstein, S. Yu, L. Pallanck, M. Davis (University of Washington)

529 Emergence of stealth polymorphs that escape α-synuclein amyloid monitoring, take over and acutely spread in neurons F. De Giorgi, F. Laferriere, F. Zinghirino, E. Faggiani, A. Lends, M. Bertoni, X. Yu, A. Gérard, E. Morvan, B. Habenstein, N. Dutheil, E. Doundnikoff, J. Daniel, S. Claverol, C. Qin, A. Loquet, E. Bezard, F. Ichas (Institute of Neurodegenerative Diseases)

530 Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy V. DJ, S. Chandra (Yale University School of Medicine)

532 Intrastriatal injection of alpha-synuclein preformed fibrils results in cognitive dysfunction and L-DOPA reversible sensorimotor impairments in rats S. Fleming, J. Patterson, L. Yan, C. Kemp, K. Miller, A. Stoll, M. Duffy, D. Herman, J. Lipton, K. Luk, J. Goudreau, C. Sortwell (Northeast Ohio Medical University)

534 Screening of mutations in PARK2 gene and Dopamine levels in Parkinson's disease (PD) patients in Coimbatore population, India I. Iyer, V. Venkatesan, V. Vellingiri (Avinashilingam Institute for Home Science and Higher Education for Women)

535 The Fragile X Mental Retardation Protein is lost prior to the appearance of Lewy pathology in Parkinson’s disease T. Koeglsperger, Y. Tan, C. Sgobio, T. Arzberger, F. Machleid, Q. Tang, E. Findeiss, J. Tost, T. Chakroun, P. Gao, M. Höllerhage, K. Bötzel, J. Herms, G. Höglinger (German Center for Neurodegenerative Diseases (DZNE))

536 The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease E. Kozina, M. Byrne, L. Oakley, R. Smeyne (Jefferson Hospital for Neuroscience, Thomas Jefferson University)

537 miRNA sequencing from routine colonic biopsies reveals an enrichment of submucosal hsa-miRNA-486-5p in Parkinson's disease A. Kurz, R. Kumar, C. Wenk, B. Nordhoff, J. Schirra, S. Donakonda, G. Höglinger, K. Bötzel, L. Holdt, T. Koeglsperger (German Center for Neurodegenerative Diseases (DZNE))

538 Alpha-synuclein DNA methylation in CD45+ blood cells in Parkinson’s disease A. Lavrinova, N. Melnikova, A. Dmitriev, I. Miliukhina, E. Litusova, P. Gagarina, O. Berkovich, S. Pchelina, A. Emelyanov (Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute»)

539 Effects of exosomes devised from dopaminergic neurons overexpressing α-synuclein on autophagy and inflammation in microglia Y. Liang, L. Bu, E. Tao (Sun Yat-sen Memorial Hospital of Sun Yat-sen University)

540 Gut Microbiota in Parkinson’s disease: influences of device-assisted therapies M. Lubomski, X. Xu, A. Holmes, J. Yang, R. Davis, C. Sue (Royal North Shore Hospital)

541 L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production S. Martin, V. Jones, J. Taylor, S. Lane, J. Ehlting, A. Helton, P. Walter (University of Victoria)

543 Loss of CHCHD2 and CHCHD10 disrupts mitochondrial cristae phenocopying patient mutations

D. Narendra, Y. Liu, X. Huang, D. Nguyen, M. Shammas, B. Wu, E. Dombi, D. Springer, J. Poulton, S. Sekine (National Institute of Neurologic Disorders and Stroke)

544 A novel peptide reduces α-synuclein levels and neurodegeneration in cell, invertebrate, and mammalian models of Parkinson’s disease D. O'Hara, S. Nim, K. Hall, M. Kapadia, M. De Snoo, H. Chau, S. Ngana, C. Corbi-Verge, A. Perez-Riba, S. Kalia, L. Kalia, P. Kim (Krembil Research Institute)

549 Compartment-specific blockade of dopamine uptake in nigrostriatal pathway reveals role for nigral dopamine function in movement frequency in open-field M. Salvatore, E. Kasanga, K. Lanza, S. Meadows, A. Centner, C. Bishop (University of North Texas Health Science Center Fort Worth)

550 α-Synuclein propagation via olfactory pathway induces olfactory bulb atrophy and widespread glucose hypometabolism in a non-human primate model M. Sawamura, H. Onoe, H. Tsukada, K. Isa, N. Uemura, T. Isa, R. Takahashi (Graduate school of Medicine, Kyoto University)

551 Profile of miRNA expression in CSF of Parkinson’s disease identifies miR-409-3p regulating the apoptosis of dopamine neurons X.L. Tan, J.Q. Tan, F.Y. Ming, L.L. Lv, H.N. Zhang, B.S. Tang, W.Q. Yan, R.R. Bai, X.K. Peng, Q.L. Xiao, C.Y. Wang (The Second Xiangya Hospital, Central South University)

553 Protective role of astrocytes on α-synuclein accumulation and propagation T. Tsunemi, Y. Ishiguro, A. Yoroisaka, K. Krainc, N. Hattori (Juntendo University School of Medicine)

554 Increased expression of conexin 36 in rodent model of Parkinson disease M. Viegas, L. Santos, F. Scorza, C. Scorza, A. Rodrigues, A. Almeida (Universidade Federal de São João del rei)

555 The Influence of 3-Phenoxybenzoic Acid in Dopaminergic Degeneration F. Wan (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)

558 Cancerous inhibitor of protein phosphatase 2A in Parkinson’s disease S.J. Yin, C. Han, T. Wang (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)

562 Spatiotemporal Changes in Substantia Nigra Neuromelanin Content from Prodromal to Clinical Parkinson’s Disease E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabrègue, C. Ewenczyk, M. Hutchison, C. François, J.-C. Corvol, M. Vidailhet, S. Lehéricy (Institut du Cerveau et de la Moelle épinière – ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université)

578 Investigating Substantia Nigra Damage using Fully Automated Segmentation of Neuromelanin MRI in Early Parkinson’s Disease R. Gaurav, R. Valabregue, L. Yahia-Cherif, N. Pyatigorskaya, G. Mangone, E. Biondetti, C. Ewenczyk, M. Hutchison, J.C. Corvol, M. Vidailhet, S. Lehéricy (Brain and Spine Institute – ICM)

591 Hyposmia as a biomarker in patients with Parkinson’s disease and atypical Parkinsonism S. Kumaran, A. Ankeeta, S. Chaudhary, P. Bhat, V. Goyal (All India Institute of Medical Sciences)

600 Graph theory analysis of dopamine D2 receptor network in Parkinson's disease patients A. Mihaescu, J. Kim, S. Cho, M. Diez-Cirarda, M. Valli, Y. Koshimori, A. Strafella (Centre for Addiction and Mental Health)

605 Parkinson's Disease Exhibits Longitudinal Increases in beta-Amyloid in the Striatum and Cingulate Gyrus J. O'Donnell, Y. Zhou, M. Campbell, B. Maiti, J. Perlmutter (Washington University School of Medicine)

614 Intrinsic Remodeling of the Fovea is Correlated with Contrast Sensitivity Loss in Parkinson’s Disease E. Pinkhardt, A. Ding, S. Slotnick, J. Kassubek, A. Ludolph, S. Glazman, I. Selesnick, I. Bodis-Wollner (Ulm University)

615 Retinal Pathology in Parkinson’s Disease: A Longitudinal Study with Optical Coherence Tomography E. Pinkhardt, F. Euler, D. Batra, J. Kassubek (Ulm University)

621 Resting State Functional and Structural Connectivity Changes of Cerebellum Basal Ganglia Interconnecting Network in Parkinson’s Disease V. Radhakrishnan, S. Krishnan, B. Thomas, C. Gallea, C. Kesavadas, A. Kishore (Sree Chitra Tirunal Institute for Medical Sciences and Technology)

633 Identifying neural signatures of Parkinson’s disease that predict decline in gait and postural control H. Sigurdsson, A. Yarnall, B. Galna, S. Lord, L. Alcock, R. Morris, R. Lawson, S. Colloby, M. Firbank, N. Pavese, D. Brooks, J. O'brien, D. Burn, L. Rochester (Newcastle University)

635 Alpha-synuclein preformed fibril (PFF)-triggered synucleinopathy recapitulates neurochemical features of human PD: A PET study in rats C. Sortwell, J. Patterson, C. Kemp, K. Miller, A. Stoll, M. Duffy, K. Luk, V. Sossi (Michigan State University)

645 Brain atrophy progression in de novo Parkinson’s disease C. Tremblay, S. Rahayel, A. Vo, A. Dagher (Montreal Neurological Institute and Hospital)

646 Neuroimaging Extra-Striatal D2 Receptors in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder M. Valli, S.S. Cho, M. Masellis, R. Chen, Y. Koshimori, M. Diez-Cirarda, A. Mihaescu, A. Strafella (Centre for Addiction and Mental Health (CAMH))

648 Progression of cortical thinning in Parkinson’s disease A. Vo, C. Tremblay, S. Rahayel, Y. Yau, A. Dagher (Montreal Neurological Institute)

651 In vivo markers of anxiety in drug-naïve Parkinson’s disease H. Wilson, E. de Natale, M. Politis (University of Exeter)

652 Microstructural changes in GBA mutation carriers with depression H. Wilson, E. de Natale, M. Politis (University of Exeter)

654 Neural Correlates of Semantic Fluency Deficits in Parkinson’s Disease with Mild Cognitive Impairment J. Yang, G. Byrne, J. O'Sullivan, K. McMahon, D. Copland, N. Dissanayaka (University of Queensland Centre for Clinical Research)

657 Effect of globus pallidus interna deep brain stimulation on functional connectivity in patients with Parkinson’s disease C.C. Zhang, N.Y. He, J. Li, Y.J. Lai, L.B. Wang, B.M. Sun, V. Voon, F.H. Yan, D.Y. Li (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)

662 Unraveling neural oscillatory changes due to STN Coordinated Reset Deep Brain Stimulation in the MPTP Non-Human Primate Model of Parkinsonism J. Bore, B. Campbell, H. Cho, M. Newcomb, R. Faulhammer, A. Machado, K. Baker (Lerner Research Institute, Cleveland Clinic)

664 Asymmetrical cochlear dysfunction as a lateralized non-motor feature in Parkinson’s disease R. Cerroni, A. Viziano, R. Sisto, A. Moleti, N.B. Mercuri, A. Stefani, M. Pierantozzi (Parkinson Centre, Department of System Medicine, University of Rome Tor Vergata)

671 Rhythmic activity of subthalamic neurons during externally and internally generated movements in Parkinson's disease

V. Filyushkina, E. Belova, S. Usova, V. Popov, A. Tomskiy, A. Sedov (N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Science)

673 Visual Motion Perception and Metacognition in Parkinson's disease O. Halperin, R. Karni, S. Israeli-Korn, S. Hassin-Baer, A. Zaidel (Bar Ilan University)

678 Lack of depotentiation may not be a hallmark of Levodopa-induced dyskinesias A. Kishore, P. James, S. Krishnan, K. Divya, S. Meunier (Sree Chitra Tirunal Institute of Medical Sciences and Technology)

681 Application of Deep Neuronal Networks for the extraction of spectral characteristics in patients with Parkinson's disease

A. Maitin, A. Garcia-Tejedor, M. Castillo, I. Serrano, E. Rocon, A. Arroyo, J. Andreo, J. Romero (CEIEC - Universidad Francisco de Vitoria)

686 The Many Faces of Bradykinesia in Parkinson’s Disease : The Quantitative Analysis from A Keyboard Typing Test P. Panyakaew, K. Duangjino, T. Ploensin, K. Piromsopa, R. Bhidayasiri (1Chulalongkorn Centre of Excellence for Parkinson’s Disease and Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital)

687 Genetic Profiling of Early Synucleinopathy in Rat Nigrostriatal Dopamine Neurons J. Patterson, C. Kemp, M. Duffy, J. Howe, C. Russell, A. Stoll, K. Miller, J. Beck, S. Counts, K. Steece-Collier, K. Luk, C. Sortwell (Michigan State University)

694 Pain syndrome in Parkinson's disease: neurophysiological and MRI morphometric features O. Alenikova, I. Goursky, N. Alenikov (Republican Scientific and Clinical Center of Neurology and Neurosurgery)

700 The role of dopamine mis-metabolism in preclinical Parkinson’s disease olfactory deficits L. Beauchamp, L. Vella, A. Bush, K. Barnham (The University of Melbourne)

710 Effects of Long-Term Treatment with Fluvoxamine on Non-Motor Symptoms and Neurogenesis in an Early Post-Natal Stress Rat Model of Parkinson’s Disease E. Dalle, W. Daniels, M. Mabandla (Universoty of KwaZulu-Natal)

729 A study of gut microbiota dynamics in Parkinsonian mice E. Klann, M. Tagliamonte, M. Ukhanova, V. Mai, V. Vedam-Mai (University of Florida)

737 Activated microglia contribute to MPTP-induced impairment of cardiovascular function X. Liu, B. Wei, Q. Sun, Q. Bi, X. Shen, P. Shi (Zhejiang Hospital)

740 Depression in Parkinson’s Disease: perspectives from an Australian cohort M. Lubomski, R. Davis, C. Sue (Royal North Shore Hospital)

766 Temporal characterization of motor, gastrointestinal, and behavioral symptoms in a SNCA A53T transgenic mouse model of Parkinson’s disease N. Radisavljevic, M. Cirstea, K. Bauer, B. Finlay (Michael Smith Laboratories, University of British Columbia)

782 Risk of Hospital Admission in Patients with Parkinson's disease Associated Psychosis (1991-2010) C. Stang, M. Hajeb, E. Camerucci, P. Turcano, A. Mullan, P. Martin, V. Abler, M. Splett, N. Rashid, J. Bower, M. Mielke, R. Savica (Mayo Clinic)

800 The role of the disorders in interaction between visual and oculomotor systems and their MRI correlation in patients with camtocormia in Parkinson's disease O. Alenikova, S. Likhachev (Republican Scientific and Clinical Center of Neurology and Neurosurgery)

803 Disease progression characterized by motor performance, dopaminergic neurodegeneration and T cell infiltration in the transgenic hm2-α-SYN-39 mouse model of Parkinson´s disease J. Behnke, L. Rauschenberger, S. Knorr, J. Volkmann, C.W. Ip (University Hospital Wuerzburg)

806 The interaction of Parkin and TAF15 for the Drosophila in which neuronal defect was induced E.J. Choi, D.G. Lee, C.C. Cui, K.Y. Kim (Department of Neurology, Ulsan University Hospital, Ulsan University College of Medicine)

807 Characterization of striatal dopaminergic neurotransmission in the rat pre-formed fibril models of Parkinson’s disease I. Del Priore, N. Chambers, M. Coyle, R. Fassler, J. Patterson, C. Kemp, A. Stoll, K. Miller, K. Luk, C. Sortwell, C. Bishop (Binghamton University)

809 Movement Disorders After Bariatric Surgeries – Case Series G. Fabiani, C.H. Camargo, H. Teive (Hospital de Clínicas, Federal University of Parana)

813 Selective α-synuclein overexpression-induced pathology in noradrenergic neurons: a new mouse model for prodromal Parkinson’s disease? B. Lee, Y. Chen, G. Ganjam, N. Decher, A. Gundlfinger, WD.J. Berg, M. Britschgi, O. Oertel (Philipps University Marburg)

814 Biomarkers for Parkinson´s Disease with Reflex Tears Correlate with Disease Duration M. Lew, S. Janga, D. Feigenbaum, D. Freire, M. Edman, W. Mack, C. Okamoto, S. Hamm-Alvarez (USC/Keck School of Medicine)

815 An objective comparison of forward and backward postural instability in early Parkinson's disease C. Lu, S. Amundsen Huffmaster, K. Louie, R. McGovern, C. MacKinnon, S. Cooper, R. Lowe, J. Vitek, R. Abulu (University of Minnesota)

821 A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression M. Niu, Y. Li, G. Li, L. Zhou, N. Luo, M. Yao, W. Kang, J. Liu (Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine)

825 An agent-based model replicates the pathogenic spread of alpha-synuclein in mice S. Rahayel, B. Mišić, Y.Q. Zheng, Z.Q. Liu, A. Caputo, K. Luk, A. Dagher (Montreal Neurological Institute and Hospital, McGill University)

826 Effectiveness of lead position with microelectrode recording based support vector machine for characterizing the sub-cortical-structures via deep brain stimulus in Parkinson`s disease V. Rama Raju (CMRCET, Jawaharlal Nehru Technological University)

828 Difference in distribution between alpha-synuclein oligomers and Lewy bodies in Parkinson’s disease brain H. Sekiya, H. Kowa, Y. Hashimoto, M. Takata, R. Matsumoto, T. Toda (Kobe University Graduate School of Medicine)

829 Spreading ɑ-synuclein pathology initiated from the sublaterodorsal tegmental nucleus models RBD followed by Parkinsonian phenotypes in mice Y. Shen, W.B. Yu, B. Shen, H. Dong, J. Zhao, Y. Fan, Y.F. Yang, Y.M. Sun, Y.L. Tang, F.T. Liu, J.J. Wu, B.G. Xiao, H. Yu, J. Koprich, Z.L. Huang, J. Wang (Huashan Hospital, Fudan University)

833 Increased epinephrine in the saliva of Parkinson’s disease patients: A preliminary observation P. Wichit, S. Thanprasertsuk, T. Hopetrungraung, O. Phokaewvarangkul, S. Bongsebandhu-phubhakdi, R. Bhidayasiri (Faculty of Medicine, Chulalongkorn University)

835 Alpha synuclein BAC transgenic mice as a preclinical model for disease-modifying therapies in Parkinson's disease H. Yamakado, S. Okuda, T. Taguchi, M. Ikuno, M. Uemura, N. Uemura, M. Hondo, M. Yanagisawa, R. Takahashi (Kyoto University Graduate School of medicine)

864 Neural activity in the subthalamic nucleus in association with reward/loss processing in patients with Parkinson's disease C.C. Zhang, J. Li, L. Manssuer, Q. Ding, L.B. Wang, B.M. Sun, D.Y. Li, V. Voon (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)

915 Morphological changes of retina in patients with Parkinson's disease and the role of α-synuclein in retinal damage L. Man, Z. Wei (The First Affiliated Hospital of Chengdu Medical College)

927 Serum microRNA expression levels in Turkish patients with Parkinson’s disease B. Ozdilek, B. Demircan (Department of Neurology, Istanbul Medeniyet University Faculty of Medicine)

945 Phase I Study Design of a Leucine-Rich Repeat Kinase 2 (LRRK2) Antisense Oligonucleotide, for Parkinson's Disease J. Shirvan (Biogen)

948 NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes T. Simuni, C. Coffey, E. Klingner, C. Caspell-Garcia, D.E. Lafontant, K. Merchant, B. Fiske, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, L. Trusso, L. Baker, M. Kostrzebski, C. Venuto, G. Rafaloff, T. Ward (Northwestern University Feinberg School of Medicine)

971 Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson's disease S. Ahmed, V. Naidu (Laboratory of Neuroscience, National Institute of Pharmaceutical Education and Research- Guwahati)

983 Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson's disease model L. Bu, Y. Lu, Y. Liang, Y. Chen, S. Peng (Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University)

987 The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study H.C. Chang, Y.C. Tsai, C.S. Lu (Professor Lu Neurological Clinic)

1014 Calcitriol Treatment Attenuates Dopaminergic Neurodegeneration in Mice Model of Parkinson’s Disease J.J. Hu, T. Wang (Affiliated Union hospital of Huazhong University of Science & Technology, Wuhan, China) 1017 Comparing the effects of rosemary and selegiline on behavioral symptoms of Parkinson’s animal model in mice M. Modaresi (Isfahan (Khorasgan) Branch, Islamic Azad University)

1021 Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy N. Kanzato, K. Nakachi, S. Mochizuki, (Okinawa Prefectural Southern Medical Center & Children’s Medical Center)

1022 Ceftriaxone improves motor function in a rat hemi-parkinsonian model: Potential to delay bilateral progression of motor deficits in Parkinson’s disease E. Kasanga, C. McElroy, M. Salvatore (University of North Texas Health Science Center)

1024

Anti-parkinson effect of natural L-DOPA

containing drug Mucuna pruriens against the

rotenone induced rat model of Parkinson's

disease

V. Kumar, F. Anwar (Sam Higginbottom University

of Agriculture, Technology & Sciences)

1032 Quantitative study of T-type Ca2+ channels in the subthalamic nucleus neurons towards Parkinson’s disease C. Mahapatra (Indian Institute of Technology Bombay)

1038 Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson's symptoms in animal model M. Modaresi (Isfahan (Khorasgan) Branch, Islamic Azad University)

1041 New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease M. Nikolaev, A. Kopytova, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, G. Rychkov, A. Cheblokov, F. Ibatullin, S. Pchelina, A. Emelyanov (Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Center «Kurchatov Institute»)

1062 Targeting the Receptor of Glial Cell Line-Derived Neurotrophic factor to treat Parkinson’s Disease Y. Sidorova, A. Mahato, M. Saarma (University of Helsinki)

1063 Characterization of novel alpha-synuclein aggregation model of Parkinson's disease A. Singh, S. Reunanen, A. Panhelainen, M. Voutilainen (University of Helsinki)

1064 Neuroprotective and neuromodulatory properties of Olea purpurea leaf extract in MPTP intoxicated Parkinsonian rat model A. Singh, T. Yadav, A. Pandey (Department of Biochemistry, University of Allahabad)

1072

Effects of a next-generation neurotrophic

compound in a toxin model of Parkinson’s

disease

T. Viljakainen, M. Saarma, M. Voutilainen (Institute

of Biotechnology, University of Helsinki)

1074 Distribution of intranasal hNSCs in a mouse model of MPTP-induced Parkinson's disease F. Wang, Y.T. Zhang, S.Z. Wei, C. Ren, C.F. Liu (Institute of Neuroscience, Soochow University)

1076 Identification and characterization of anti-prionic compounds that disassemble αSyn prions as a novel therapeutic approach for synucleinopathies D. Willbold, M. Sevenich, W. Hoyer, J. Mohrlüder, A. Willuweit (Forschungszentrum Jülich)

1080 Automated classification of neurodegenerative parkinsonian syndromes using multimodal magnetic resonance imaging in a clinical setting L. Chougar, J. Faouzi, N. Pyatigorskaya, O. Colliot, S. Lehéricy (Institut du cerveau et de la moelle, Sorbonne Université, Paris, France)

1084 Age and gender differences in cardiovascular autonomic failure in transgenic PLP-syn mouse model of multiple system atrophy M. Kermorgant, D. Arvanitis, P.O. Fernagut, W. Meissner, J.M. Senard, C. Galès, A. Pavy-Le Traon (Institut des Maladies Métaboliques et Cardiovasculaires)

1086 Sleep-related Symptoms in Multiple System Atrophy: Determinants and Impact on disease severity J.Y. Lin, L.Y. Zhang, B. Cao, Q.Q. Wei, H.F. Shang (West China Hospital, Sichuan University)

1087 CHCHD2 mRNA levels in erythrocyte are reduced in patients with multiple system atrophy G.l. Liu, X.d. Liu, T. Feng (Beijing Tiantan Hospital, Capital Medical University)

1098 GCI-induced neurodegeneration and synucleinopathy in non-human primates M. Teil, S. Dovero, M.L. Artocarena, M. Bourdenx, G. Porras, B. Mollenhauer, M.T. Herrero, M. Vila, J. Obeso, B. Dehay, E. Bezard (Institute of Neurodegenerative Diseases)

1124 Temporhythmal Correction: The New Way of Therapy and Diagnostic Secondary Vascular Parkinsonism D.T. Akramova (Tashkent Medical Academy)

1130

The effect of comorbid NPH on the clinical

feature and progression of Parkinson's disease

A. Hattori, T. Tsunemi, Y. Ishiguro, N. Hattori

(Juntendo University School of Medicine)

1132 Development and validation of a profile of peripheral immune biomarkers for Parkinson’s disease: A multicenter, retrospective study Y. Li, J. Liu (Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine)

1134 Microbiome from Parkinson’s patients shows an increase in polyamines metabolism and differentially expresses microbial bacterial taxa compared to aged-matched normal controls S. Melgar, N. Danso, C. Pena, J. Ahmed, S. Kumar, R. Kumar, C. Carlin, D. Linseman, D. Paredes (Knoebel Institute for Healthy Aging, University of Denver)

1136 Staircase sign for Atypical and Secondary parkinsonism Y.S. Oh, J.S. Kim, D.Y. Kwon, M.H. Park, B.R. Bloem (College of Medicine, The Catholic University of Korea)

1141 Intracranial Tuberculous Abcess with Acute Parkinsonism: Unusual Finding K.K. Shahedah, A. Nurul Asyikin (Faculty of Medicine, International Islamic University Malaysia(IIUM))

1149 Circadian rhythm alterations in an in vitro cellular model of Spinocerebellar ataxia type 17 F. Motolese, A. Casamassa, A. Vescovi, V. Di Lazzaro, J. Rosati, M. Marano (Università Campus Bio-Medico di Roma)

1150 Changes in the AKT/GSK3 pathway in the cerebellum increase susceptibility to movement disorders in a rat model of post-traumatic stress disorder G. Ngoupaye, M. Mabandla (College of health Science, University of Kwazulu-Natal)

1155 Visuospatial training improved the visuospatial abilities in child with cerebral palsy: case report S. Kiselev (Ural Federal University)

1160 Inter-relation between hand functioning, cognition and quality of life of CP children: 2-year prospective randomized study T. Voloshyn, V. Kozyavkin, L. Shestopalova (Kozyavkin Medical Rehabilitation Clinic)

1176 Cortical Activation during Dynamic Sway of young Fragile X Premutation Carriers C. O'Keeffe, M. Carro Domínguez, E. O'Rourke, T. Lynch, T. Reilly (Trinity Centre for Bioengineering, Trinity College Dublin) 1185 The Feasibility of Using of the Non-Medication in the Treatment of Post-Stroke Vascular Parkinsonism O. Tondiy, O. Zavalna (Kharkiv Medical Academy of Postgraduate Education, Ukraine)

1187 Challenge Point Guide: Characterizing exercises performed in multilevel Parkinson-specific community exercise classes E. Borchers, J. Goodwin, J. Bazan-Wigle, T. McIsaac, B. Farley (Parkinson Wellness Recovery)

1221 Brain activity underpinning visual cues for gait impairment in Parkinson’s disease S. Stuart, J. Wagner, S. Makeig, M. Mancini (Oregon Health and Science University)

1242 Comparative analysis of the quality of life between healthy elderly people and those with Parkinson’s disease L. Santos, A. Alonso, N. Luna, J. Greve (Universidade Anhembi Morumbi)

1257 A translational approach to determine target concentrations of MIN-102 (leriglitazone) to support a Phase II study in Friedreich’s ataxia

S. Poli, L. Rodríguez-Pascau, J. Ros, P. González-Cabo, E. Britti, D. Lynch, G. Pina, S. Pascual, M. Cerrada-Gimenez, D. Eckland, E. Traver, J. Wetering-de-Rooij, M. Martinell, U. Meya, P. Pizcueta (MInoryx Therapeutics BE)

1283 Bruxism Associated with Restless Limbs Syndrome (RLS): A Dopamine Responsive Movement Disorder D. Dickoff, S. Dontje, R. Sirkin, N. Ditkoff (Metropolitan Neurological Consultants, PC)

1294 Neuronal Inclusion Formation and Axonal Degeneration in Mutant TFG Transgenic Mice T. Kawarai, A. Orlacchio, R. Kaji (Institute of Biomedical Sciences, Tokushima University Graduate School)

1295 Heterozygous mutation in CCDC88C gene as a cause of early onset pure hereditary spastic paraplegia A. Mohamed, S. Emad, R. Adil, L. Elsayed, A. Ahmed, G. Stevanin (Faculty of Medicine, University of Khartoum)

1296 Transcutaneous spinal cord current stimulation modulate Reactive Oxygen Species (ROS) in multiple sclerosis patients S. Mrakic-Sposta, R. Ferrucci, S. Floro, F. Ruggiero, M. Vergari, S. Versace, S. Santoni, A. Vezzoli, M. Massei, M. Deriz, S. Marceglia, S. Barbieri, A. Priori (National Research Council Unit - Institute of Clinical Physiology Milan- (CNR-IFC))

1299 New tool to localize seizure onset zone from sEEG signal-connectivity epileptogenicity index A. Balatskaya (National Medical Surgery Center named after Pirogov)

1331 Long-term effect of deep brain stimulation in a monkey model of Parkinson’s disease with L-Dopa–induced dyskinesias M. Bourque, S. Carrondo-Cottin, M. Parent, L. Cantin, B. Gosselin, M.E. Tremblay, T. Di Paolo (CHU de Quebec-Université Laval)

1346 Plasticity of frequency dependent tremor control in Parkinson disease (PD) subthalamic nucleus (STN) deep brain stimulation (DBS) implanted individuals E. Hargreaves, D. Schneider, R. DiPaola, J. Chen, S. Danish, D. Caputo (Rutgers University -- Robert Wood Johnson Medical School)

1365 Intraoperative test objectively for discovering optimal electrode site for effective imaging (by eye) and bilateral STN-DBS stereotactic functional neurosurgery V. Rama Raju, L. Neerati, A. Dabbeta, H. Yeruva, S. Konda, N. Guguloth (CMR College of Engineering & Technology (JNTUH) & NIMS Hospital)

1366 Objective study of intra operative test for discovering optimal electrode site for effective imaging and bilateral STN-DBS stereotactic functional neurosurgery V. Ramaraju (CMR College of Engineering & Technology, and Nizam`s Institute of Medical Sciences (NIMS) Hospital)

1377 Neuropathological Changes Following PPN Region DBS V. Vedam-Mai, A. Elkouzi, S. Prokop, A. Yachnis, K. Foote, L. Almeida, A. Ramirez-Zamora, M. Okun (University of Florida)

1385 Single-energy Metal Artefact Reduction: a Precise Method for Localization of Deep Brain Stimulation Electrodes in Parkinson’s Patients W. Xian, L. Chen, J. Liu, C. Yang (The First Affiliated Hospital, Sun Yat-Sen University)

1386 Voltage Adjustment Effects More on Limb Symptoms than Axial Symptoms in Parkinson’s Disease Patients Treated with Subthalamic Nucleus Stimulation W. Xian, L. Chen, J. Liu, C. Yang (The First Affiliated Hospital, Sun Yat-Sen University)

1398 Automated Capture of Deep Brain Stimulation Settings & Clinical Outcomes K. Castell, C. Butson (University of Utah)

1400 Bioengineered nigrostriatal constructs model Lewy pathology E. Clark, L. Struzyna, W. Gordián-Vélez, I. Chen, K. Cullen, J. Duda (Michael J. Crescenz VA Medical Center)

1413 Efficacy of a Vibrational Armband in Maintenance of Forced Arm Swing in Parkinsonism A. Harbour, J. VanWart, Z. Mercer, K. Pique, R. Golan, J. Clark, C. Maitland (FSU College of Medicine)

1443 The Unique Voiceprint Changed In Parkinson’s Disease F. XU (Chengdu medical college)

1444 The diagnostic value of smartphone-based instrumented Timed Up & Go test in different movement disorders

G. Yahalom, S. Israeli-Korn, T. Fay-Karmon, V. Livneh, K. Tchelet, Z. Yekutieli, A. Stark-Inbar, S. Hassin-Baer, H. Yahalom, M. Linder (Shaare Zedek Medical Center)

1448 A novel easily performed objective test of fine motor skill in handwriting and drawing to support diagnosing Parkinson’s disease R. Zietsma, S. Bojic, A. Karki, R. Bauer, M. van Gils, L. Cluitmans, A. Tolonen, R. Walker, K. Gray (Manus Neurodynamica Ltd)

1449 A C12orf65 mutation-related autosomal recessive hereditary spastic paraplegia is associated with autophagy induction L. Wu, Y. Xu, Q. Wang, X. Lai, I. Vinnikov, W. Chen (Department of Neurology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine)

1451 Children with Tourette syndrome show greater variability in an arm-position-matching proprioceptive task N. Cothros, A. Medina, D. Martino, S. Dukelow, R. Hawe, A. Kirton, E. Nosratmirshekarlou, T. Pringsheim (University of Calgary)

1456 Endocrine Predicts of the Formation of Complex Motor Tics in Tourette’s Disease D. Labunskiy, E. Yurasova, N. Kurgaev, S. Kiryukhina, V. Podsevatkin, D. Baranov (Neurology and Psychiatry, N.P. Ogarev Mordovia State University, Saransk, Russia)

1458 Cerebellar structural covariance networks in young people with Tourette syndrome H. Sigurdsson, S. Jackson, L. Jolley, E. Mitchell, G. Jackson (University of Nottingham)

1469 Can bedside neurophysiological testing aid the differential diagnosis of bilateral upper limb action tremors in young-onset patients? T. Dang, P. Panyakaew, R. Bhidayasiri

1474 Efficacy and safety of CX-8998 in T-CALM, a randomized, double-blind, placebo-controlled, phase 2a trial in participants with essential tremor: subgroup analysis by baseline tremor severity H. Jinnah, S. Papapetropoulos, M. Lee, S. Versavel, E. Newbold, R. Pahwa, K. Lyons, R. Elble, W. Ondo, T. Zesiewicz, P. Hedera, A. Handforth, J. Elder, M. Versavel (Emory University School of Medicine)

1482 No frank biochemical evidence of proteinopathy in the cerebellar cortex of patients with essential tremor K. Melançon, A. Rajput, A. Rajput, C. Tremblay, F. Calon, E. Aubry-Lafontaine, E. Brochu, S. Paris-Robidas (Centre de recherche du CHU de Québec – Université Laval)

1483 Post mortem fatty acid abnormalities in the cerebellar cortex of patients with essential tremor K. Melançon, L. Berthiaume, C. Tremblay, P. Juline, A. Rajput, A. Rajput, F. Calon (Université Laval)

1487 The pathophysiology of dystonic tremors and comparison with essential tremor P. Panyakaew, H.J. Cho, S.W. Lee, M. Hallett (Chulalongkorn Center of Excellence for Parkinson’s Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society)